Ask AI
ProCE Banner Activity

Evolving Treatment Paradigms in Endometrial Cancer: Immunotherapy, ADCs, and Precision Sequencing in Clinical Practice

Slideset

These downloadable slides provide evidence on antibody–drug conjugates in endometrial cancer and present information about the molecular classification of endometrial cancer, algorithms for first-line and second-line therapy and data from clinical trials like GOG-3031/RUBY, NRG-GY018/KEYNOTE-868, and DUO-E/GOG-3041/ENGOT-EN10. In addition, the toxicities associated with antibody–drug conjugates are outlined. Major disparities in endometrial cancer with incidence, outcomes, and biomarkers are also highlighted.

Released: November 03, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from Gilead Sciences, Inc. and Merck Sharp & Dohme LLC.

Gilead Sciences, Inc.

Merck Sharp & Dohme, LLC

Target Audience

This educational activity is intended for oncologists and other healthcare professionals who care for patients with endometrial cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply current molecular and biomarker testing recommendations, including MMR/MSI, POLE, p53, HER2, ER/PR, and selected actionable alterations, to guide risk assessment, treatment selection, and sequencing in advanced or recurrent endometrial cancer

  • Differentiate approved and guideline-supported immunotherapy-based regimens for primary advanced or recurrent endometrial cancer by MMR/MSI status, histology, comorbidities, toxicity profile, maintenance strategy, and prior treatment exposure

  • Evaluate emerging ADC data in endometrial cancer, including TROP2-, B7-H4-, and HER2-directed approaches, with attention to mechanism of action, evidence maturity, safety considerations, biomarker context, and potential roles after prior platinum and immunotherapy

  • Implement practical strategies to reduce disparities in endometrial cancer care by improving access to molecular testing, gynecologic oncology consultation, clinical trials, toxicity management support, and guideline-concordant systemic therapy